News

FDA approved safinamide (Xadago, Newron Pharmaceuticals) tablets as an add-on treatment for patients with Parkinson’s disease. FDA also approved new treatments for classical Hodgkin lymphoma and pemphigus vulgaris, a rare, life-threatening condition characterized by progressive painful blistering of the skin and mucous membranes.

Here are five critical regulations that executives can begin to prepare for today.

Researchers create a set of recommendations for transparency at the agency in five principal areas.

To ensure providers are prepared for telemedicine practice, healthcare leaders must provide training in these areas.

Healthcare leaders are concerned about developing reliable strategies for the future. Is effective strategic and financial planning even possible with so many variables up in the air?

With ACA repeal and replace on the horizon, digital healthcare solutions will surely be affected.

What should managed care executives know about the GOP ACA replacement plan? Find out.

A West survey finds that an overwhelming number of chronic care patients say they need help managing their disease.

Pharmaceutical manufacturers and some consumer groups praised President Donald Trump’s nomination of Dr. Scott Gottlieb as the new FDA commissioner.

Mylan received approval from FDA to market its desvenlafaxine extended-release tablets, the generic version of Pristiq (Pfizer), for major depressive disorder. Plus, 2 other manufacturers recently received approval for their generic versions of Pristiq.

ACA repeal or replacement must focus on how to preserve mental health services and pharmacy access.

Creating a system where health outcomes are paramount is key. Here’s what stakeholders need to do.

Innovation in healthcare wearables continues to drive market growth.

New treatment indications are under investigation for the use of cannabinoid-based drugs.

Industry leaders share their go-to strategies.

Seven ways health execs can prepare for the future.

While Trump has touted Obamacare as a “disaster,” some healthcare experts say the change could negatively impact hospitals in a variety of ways.

FDA approved 10 mg dapagliflozin and 5 mg saxagliptin (Qtern, AstraZeneca), to treat type 2 diabetes.

FDA recently approved three novel drugs: one to treat frequent urination at night, one to treat carcinoid syndrome diarrhea in cancer patients, and one for dust mite allergies. Here are the details on the three new treatments.

Health plans of the future will focus on consumers: designing products, care and services to support improved health.

Integrating businesses is complex, but experts shed light on other options including partnerships and shared services.

CMS launched the Comprehensive Care for Joint Replacement Model (CJR) in 2016.

The proliferation of specialty drugs has prompted new techniques for keeping costs in tow.

Biomarker testing for harmful genetic mutations provides the opportunity to identify at-risk individuals who might benefit from risk modification strategies and/or enhanced disease screening.

New treatment indications are under investigation for the use of cannabinoid-based drugs. Are you ready?

Stephen Rioseco, of Horizon BCBSNJ, tells Managed Healthcare Executive how his health plan fully capitalizes on the power of social media for customer service.

A dual-drug regiment to treat HIV could soon be a reality, according to results presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.

FDA recently approved 2 tests that will aid healthcare providers in determining which antibiotics are needed, leading to better antibiotics management.